When comparing the two arms , imatinib therapy was associated with higher RFS in patients with a KIT exon @ deletion of any type , but not a KIT exon @ insertion or point mutation , KIT exon @ mutation , PDGFRA mutation , or wild-type tumor , although some of these patient groups were small .